{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cervical-screening/management/cervical-screening/","result":{"pageContext":{"chapter":{"id":"ba0780ef-6124-5552-b202-75eebabe99e3","slug":"cervical-screening","fullItemName":"Scenario: Cervical screening","depth":2,"htmlHeader":"<!-- begin field 32ddd94e-c450-468a-bae5-3fffe3983837 --><h2>Scenario: Cervical screening</h2><!-- end field 32ddd94e-c450-468a-bae5-3fffe3983837 -->","summary":"Covers information on which women should have cervical screening through the NHS Cervical Screening Programme and how often, when it should be delayed, and how a cervical sample should be taken.","htmlStringContent":"<!-- begin item 59dfd65a-94c6-408b-8904-1249fce60732 --><!-- begin field e79a3da3-c819-48b4-90e5-acbc01573be8 --><p>From age 25 years to 65 years (Female).</p><!-- end field e79a3da3-c819-48b4-90e5-acbc01573be8 --><!-- end item 59dfd65a-94c6-408b-8904-1249fce60732 -->","topic":{"id":"6eb2d6d6-d121-574a-8070-e380a54d0dd0","topicId":"7394dee4-4555-4874-bb15-5ac5d86ed7d9","topicName":"Cervical screening","slug":"cervical-screening","lastRevised":"Last revised in September 2020","chapters":[{"id":"2fe43b2a-0956-5a22-a141-2c23ff8702d1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5da2ce64-4373-5a2d-a1a6-3f3bbdf2bf7c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7b70a539-14d0-50b6-93cc-edbf89ec4bc3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"576d9368-458f-5490-8bdf-666b91a7e37a","slug":"changes","fullItemName":"Changes"},{"id":"bcd50065-ad13-5af2-8473-de68a499f070","slug":"update","fullItemName":"Update"}]},{"id":"c2a0a95f-2a9b-5c96-a2b0-d26471380d35","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e98fda8-7c58-5f08-8d78-770e7406cc2b","slug":"goals","fullItemName":"Goals"},{"id":"aac1adb6-9e3a-50e6-976b-3d8be05b4f28","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b4286b35-0cba-5c8d-b4c0-55905649e5ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"32c01e99-78fd-50ce-a1b4-3fd4edcb1ecb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d0510235-ec88-5b0a-9a2e-4ad7888d78be","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5c4e6833-b040-537b-a32b-54b1317aa217","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b8be2709-4f11-5914-bcf3-e1a1d79fd23f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6d7d120d-e785-5601-9d0e-e08e28d89528","slug":"cervical-screening-programme","fullItemName":"Cervical screening programme"},{"id":"b6a7bd00-5536-5a5d-b7f3-fe1ac9685d22","slug":"cervical-screening-system","fullItemName":"Cervical screening system"}]},{"id":"5cc77439-27cd-51ff-9a06-857c9da72416","fullItemName":"Management","slug":"management","subChapters":[{"id":"ba0780ef-6124-5552-b202-75eebabe99e3","slug":"cervical-screening","fullItemName":"Scenario: Cervical screening"},{"id":"cb3f22ee-57b6-5cf4-aed8-3471ae0e9a9c","slug":"managing-hpv-cervical-cytology-results","fullItemName":"Scenario: Managing HPV and cervical cytology results"}]},{"id":"a5410c1d-84f3-5826-8512-481fd075d2a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5aade9cf-191d-5481-a6fc-cc57568100f2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2e666af8-5f3b-576d-b97c-d4a65b6bb80e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b3806c5f-8045-5cf8-a395-aea0d965082b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"df251649-2597-5c2e-8fb1-5740228d0346","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"58fed207-e499-59b9-99ec-0b1dd974fe5e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"26cba24b-2a00-54c4-b253-3e851f0fbcba","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7cf3b493-5fcc-5741-878b-5f094a762815","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5cc77439-27cd-51ff-9a06-857c9da72416","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"da920a31-4637-5359-a9a0-01c9030fde84","slug":"routine-cervical-screening","fullItemName":"Routine cervical screening","depth":3,"htmlHeader":"<!-- begin field c9bde3ca-5bb0-485f-b4ca-b2339967c9fb --><h3>Who should be called for routine cervical screening?</h3><!-- end field c9bde3ca-5bb0-485f-b4ca-b2339967c9fb -->","summary":null,"htmlStringContent":"<!-- begin item 0bcb58b6-7c2b-4512-aad6-7fc7a7e3b1ce --><!-- begin field da74e613-41ad-417d-b1a7-b704e1f1a00f --><ul><li>The NHS Cervical Screening Programme (NHSCSP) offers screening for all women between the ages of 24.5 years and 64 years at different intervals depending on their age:<ul><li>Age 24.5 years — first invitation to ensure women can be screened before they are aged 25 years.</li><li>Age 25–49 years — screening every 3 years. <ul><li>Once primary HPV screening has been fully implemented, this interval will be extended to every 5 years. </li></ul></li><li>Age 50–64 years — screening every 5 years.</li><li>Women 65 years of age or older are invited if: <ul><li>A recent cervical cytology sample is abnormal.</li><li>They have not had a cervical screening test since 50 years of age and they request one.</li></ul></li></ul></li><li>Women with cervical stenosis — refer to the colposcopy clinic for consideration of cervical dilatation.</li><li>Women with a cervix that cannot be visualized — refer for colposcopy.</li><li>Transgender men who have retained their cervix — these men should be included in the NHSSCP unless they have made an informed decision to opt out.<ul><li>The GP should take responsibility for the screening process and notify the laboratory to return the results to the practice and not the call and recall service.</li></ul></li><li>Non-binary individuals must be invited by the GP practice to participate — the current registration system is unable to record this gender category.</li><li>Women can withdraw from the programme voluntarily by written request. However, they should be provided with sufficient information to enable them to make an informed decision.</li><li>Unscheduled cervical screening does not form part of the NHSCSP unless the woman is immunosuppressed, where more frequent screening may be required. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/cervical-screening/management/cervical-screening/#cervical-screening-if-immunosuppressed\">Cervical screening if immunosuppressed</a>.</li><li>If the woman has symptoms or signs of possible gynaecological cancer, urgent referral and assessment of the cervix is required.<ul><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cervical-cancer-hpv/\">Cervical cancer and HPV</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a>.</li></ul></li></ul><!-- end field da74e613-41ad-417d-b1a7-b704e1f1a00f --><!-- end item 0bcb58b6-7c2b-4512-aad6-7fc7a7e3b1ce -->","subChapters":[{"id":"a7a3ae49-9207-57ce-a0ac-b30b8e494622","slug":"basis-for-recommendation-2a9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 17ac199f-bc75-4758-9ca9-8fcabc98e9e9 --><h4>Basis for recommendation</h4><!-- end field 17ac199f-bc75-4758-9ca9-8fcabc98e9e9 -->","summary":null,"htmlStringContent":"<!-- begin item 2a96f3d6-7b96-4cc5-8dd9-89d4aedfb24b --><!-- begin field c7ec4993-edbf-4352-9227-740a53d953fa --><p>These recommendations are based on the Public Health England (PHE) guidelines <em>NHS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2020</a>] and <em>NHS Cervical screening programme guidance for the training of cervical sample takers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016a</a>], and <em>The Green Book: human papillomavirus (HPV) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2014</a>].</p><h5>Refer women with cervical stenosis to colposcopy</h5><ul><li><p>It may not be possible to obtain a cytology sample that represents the entire transformation zone from women who have severe cervical stenosis. Cervical dilatation may be required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016b</a>].</p></li></ul><!-- end field c7ec4993-edbf-4352-9227-740a53d953fa --><!-- end item 2a96f3d6-7b96-4cc5-8dd9-89d4aedfb24b -->","subChapters":[]}]},{"id":"1fd52070-65ec-5b22-be07-12fc47a88f3d","slug":"when-to-reschedule-cervical-screening","fullItemName":"When to reschedule cervical screening","depth":3,"htmlHeader":"<!-- begin field 9b1b8946-8e42-4117-8876-f321389bc406 --><h3>When should cervical screening be delayed?</h3><!-- end field 9b1b8946-8e42-4117-8876-f321389bc406 -->","summary":null,"htmlStringContent":"<!-- begin item 6b144201-0ada-4314-b5c0-b83fedfd15a7 --><!-- begin field b339b468-0c95-4992-b684-51d9179834e7 --><ul><li><strong>A cervical sample should not be taken (unless you think the woman will not re-attend), if the woman:</strong><ul><li>Is menstruating.</li><li>Is less than 12 weeks postnatal.</li><li>Is less 12 weeks after a termination of pregnancy, or miscarriage.</li><li>Has a vaginal discharge or pelvic infection — treat the infection and take the sample on another occasion.</li></ul></li><li>If the woman is pregnant, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/cervical-screening/management/cervical-screening/#cervical-screening-if-pregnant\">Cervical screening if pregnant</a>.</li></ul><!-- end field b339b468-0c95-4992-b684-51d9179834e7 --><!-- end item 6b144201-0ada-4314-b5c0-b83fedfd15a7 -->","subChapters":[{"id":"d2dad428-51e9-5b4f-86b9-4915fb95a24f","slug":"basis-for-recommendation-3fd","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 45dd4ae7-2e41-46c6-81e9-462e604f4d41 --><h4>Basis for recommendation</h4><!-- end field 45dd4ae7-2e41-46c6-81e9-462e604f4d41 -->","summary":null,"htmlStringContent":"<!-- begin item 3fd37b26-edbb-4b07-9c8a-fee63c7ae180 --><!-- begin field 4a996418-d436-474b-9eab-b510a538a40a --><p>These recommendations are based on the Public Health England (PHE) <em>NHS Cervical Screening Programme: guidance for the training of cervical sample takers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016a</a>].</p><!-- end field 4a996418-d436-474b-9eab-b510a538a40a --><!-- end item 3fd37b26-edbb-4b07-9c8a-fee63c7ae180 -->","subChapters":[]}]},{"id":"cd5c06b1-30a2-5fd8-bc4f-d11bf5e4718e","slug":"how-to-take-a-cytology-sample","fullItemName":"How to take a cytology sample","depth":3,"htmlHeader":"<!-- begin field 31d4c51a-3813-410e-bb65-b777ae84b740 --><h3>How do I take a cytology sample for cervical screening?</h3><!-- end field 31d4c51a-3813-410e-bb65-b777ae84b740 -->","summary":null,"htmlStringContent":"<!-- begin item 07ee0aac-7cac-40fe-8c75-d5c52de8da09 --><!-- begin field 74722a3a-63e7-410a-b99b-cb0667af4e61 --><ul><li><strong>Before taking a cytology sample:</strong><ul><li>All healthcare professionals should ensure that they are competent to do so and have undergone the appropriate training.</li><li>All women should be given information and advice to enable them to make an informed choice about whether to accept the offer of screening.  <ul><li>A patient information leaflet, <a href=\"https://www.gov.uk/government/publications/cervical-screening-description-in-brief\" data-hyperlink-id=\"3ada104a-d080-4789-bd8e-a99300077c70\">NHS cervical screening: helping you decide</a> is sent with screening invitations. It is available to download in a number of languages.</li></ul></li></ul></li><li><strong>To take a cytology sample:</strong><ul><li><strong>Visualize the cervix (using a speculum) </strong>—<strong> </strong>if the cervix appears abnormal, suggesting possible malignancy, arrange urgent referral (within 2 weeks) to a gynaecologist.<ul><li><strong>Note: </strong>there is no need for referral for colposcopy if there has been contact bleeding at the time a cervical sample is obtained (in the absence of other symptoms). For more information, see the <a class=\"topic-reference external-reference\" href=\"/topics/cervical-cancer-hpv/diagnosis/\">Diagnosis</a> and <a class=\"topic-reference external-reference\" href=\"/topics/cervical-cancer-hpv/diagnosis/referral/\">Referral</a> sections in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cervical-cancer-hpv/\">Cervical cancer and HPV</a>.</li></ul></li><li><strong>Take a sample from the whole of the transformation zone.</strong><ul><li>The transformation zone can be identified by visual inspection as there is a change in colour and texture from the pale, pink, shiny, smooth surface of the ectocervix to a reddish, granular appearance of the columnar cells that line the endocervical canal.</li><li>The position of the transformation zone may be affected by age and pregnancy. </li></ul></li></ul></li></ul><!-- end field 74722a3a-63e7-410a-b99b-cb0667af4e61 --><!-- end item 07ee0aac-7cac-40fe-8c75-d5c52de8da09 -->","subChapters":[{"id":"5f49de8d-9c9a-5b6f-9c23-8b38791487bf","slug":"basis-for-recommendation-4c3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 67990707-94bf-4cf4-a008-d09a0286d55e --><h4>Basis for recommendation</h4><!-- end field 67990707-94bf-4cf4-a008-d09a0286d55e -->","summary":null,"htmlStringContent":"<!-- begin item 4c33f12c-b4f8-47df-a917-d62212fdee4e --><!-- begin field 854a49d7-db85-4f12-aff4-321436dcc40e --><p>These recommendations are based on the Public Health England (PHE) guidelines <em>NHS Cervical screening programme: guidance for the training of cervical sample takers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016a</a>] and <em>NHS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016b</a>], and a Canadian clinical guideline <em>Cervical cancer screening</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">TOP, 2016</a>].</p><ul><li>Cytology samples are taken from the transformation zone because most cervical pre-cancer and cancer develops in the squamo-columnar junction. Cells in this area are always dividing and are at risk of abnormal changes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">TOP, 2016</a>].</li></ul><!-- end field 854a49d7-db85-4f12-aff4-321436dcc40e --><!-- end item 4c33f12c-b4f8-47df-a917-d62212fdee4e -->","subChapters":[]}]},{"id":"8104f5a9-be44-545c-b3c4-5310f6c5ae5e","slug":"cervical-screening-if-pregnant","fullItemName":"Cervical screening if pregnant","depth":3,"htmlHeader":"<!-- begin field f2b2f530-b48b-4b43-a222-bb7178191552 --><h3>Should a pregnant woman be offered cervical screening?</h3><!-- end field f2b2f530-b48b-4b43-a222-bb7178191552 -->","summary":null,"htmlStringContent":"<!-- begin item fb538b3d-cd2a-4afb-9b8b-a7436eb4c761 --><!-- begin field a111d945-3e43-48b7-a459-6b557b038d54 --><ul><li><strong>If a woman has been called for routine screening and she is pregnant </strong>—<strong> </strong>reschedule the test for when she is at least 3 months post-partum.</li><li><strong>If a previous test was abnormal and in the interim the woman becomes pregnant </strong>— colposcopy should not be delayed.<ul><li>Women may undergo colposcopy in late first, or early second trimester, unless there is a clinical contraindication. However, for low-grade changes, the assessment may be delayed until after delivery.</li><li>Women seen in early pregnancy may require a further assessment in the late second trimester.</li></ul></li></ul><!-- end field a111d945-3e43-48b7-a459-6b557b038d54 --><!-- end item fb538b3d-cd2a-4afb-9b8b-a7436eb4c761 -->","subChapters":[{"id":"7b4a6eed-d05b-55db-b344-eef4ce21578c","slug":"basis-for-recommendation-285","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 040b8fe9-f066-40fe-b329-706f2e5bb819 --><h4>Basis for recommendation</h4><!-- end field 040b8fe9-f066-40fe-b329-706f2e5bb819 -->","summary":null,"htmlStringContent":"<!-- begin item 28570b06-9894-4892-b58e-6d1208df322f --><!-- begin field 16397660-483b-4b45-8903-936bb21349c8 --><p>These recommendations are based on the Public Health England (PHE) guidelines <em>NHS Cervical screening programme: guidance for the training of cervical sample takers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016a</a>] and N<em>HS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016b</a>].</p><!-- end field 16397660-483b-4b45-8903-936bb21349c8 --><!-- end item 28570b06-9894-4892-b58e-6d1208df322f -->","subChapters":[]}]},{"id":"c01b85b4-f3d0-5009-95aa-1b12331d06b6","slug":"cervical-screening-post-hysterectomy","fullItemName":"Cervical screening post-hysterectomy","depth":3,"htmlHeader":"<!-- begin field 40f88cb9-33b8-4813-bd13-9cf29e357861 --><h3>Should women who have had a hysterectomy be offered cervical screening?</h3><!-- end field 40f88cb9-33b8-4813-bd13-9cf29e357861 -->","summary":null,"htmlStringContent":"<!-- begin item 3024d8aa-fafd-4372-bdd8-a43756ab6da9 --><!-- begin field 0af291b8-e8bb-478a-b5d9-e71e8eec78a3 --><ul><li>Women who have had a:<ul><li><strong>Subtotal hysterectomy (that still have a cervix) should continue in the National Cervical Screening Programme (NHSCSP).</strong></li><li><strong>Total hysterectomy (no longer have a cervix) are not required to take part in the NHSCSP.</strong><ul><li>After a hysterectomy, the secondary care team will decide what follow-up is required. The type and frequency of follow-up depend on the reason for the hysterectomy and if cervical intraepithelial neoplasia (CIN) was found in the hysterectomy specimen.</li></ul></li></ul></li><li>Women who have had a hysterectomy with CIN present are potentially at risk of developing vaginal intraepithelial neoplasia (VaIN) and invasive vaginal disease, the NHSCSP recommends the following follow up for women who have had a total hysterectomy:<ul><li>Women on routine recall with no CIN in their hysterectomy specimen do not need further follow up.</li><li>Women not on routine recall with no CIN in their hysterectomy specimen should have vault cytology 6 months after surgery.<ul><li>If this is negative, no further screening is necessary.</li></ul></li><li>Women with CIN which has been completely excised should be offered vault cytology 6 and 18 months after surgery.<ul><li>If test results are negative at both time points, no further follow up is necessary.</li></ul></li><li>Women with CIN which has not been completely excised, or excision is uncertain, should be followed up as if their cervix remained in situ and offered:<ul><li>If high-grade disease (CIN 2 or CIN 3): cytology at 6, and 12 months, followed by annual cytology for 9 years (follow up continues to age 65 years, or until 10 years after surgery, whichever is later). </li><li>If low-grade disease (CIN 1): cytology at 6, 12, and 24 months.</li></ul></li></ul></li></ul><!-- end field 0af291b8-e8bb-478a-b5d9-e71e8eec78a3 --><!-- end item 3024d8aa-fafd-4372-bdd8-a43756ab6da9 -->","subChapters":[{"id":"e111269b-a628-5852-b3f9-be24856f0dcb","slug":"basis-for-recommendation-ba6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 195d1c8f-376e-417f-b433-87b73a0f001b --><h4>Basis for recommendation</h4><!-- end field 195d1c8f-376e-417f-b433-87b73a0f001b -->","summary":null,"htmlStringContent":"<!-- begin item ba6338cc-0ae8-4480-8acb-8449bdff8925 --><!-- begin field c180bf69-337b-4108-b035-51abfc6a3fb3 --><p>These recommendations are based on the Public Health England (PHE) guideline <em>NHS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016b</a>].</p><!-- end field c180bf69-337b-4108-b035-51abfc6a3fb3 --><!-- end item ba6338cc-0ae8-4480-8acb-8449bdff8925 -->","subChapters":[]}]},{"id":"8b4d73a8-69ae-52dd-8770-40f4c5538167","slug":"cervical-screening-if-immunosuppressed","fullItemName":"Cervical screening if immunosuppressed","depth":3,"htmlHeader":"<!-- begin field 59ba6964-26aa-48d7-b0a3-d89faeb30029 --><h3>Should women who are immunosuppressed be offered more frequent cervical screening?</h3><!-- end field 59ba6964-26aa-48d7-b0a3-d89faeb30029 -->","summary":null,"htmlStringContent":"<!-- begin item 01510e7b-2908-469c-bc20-817cfc98c089 --><!-- begin field e7601529-3bd6-4bed-8947-30d0a68f79cf --><ul><li>Offer cervical screening to women aged 25–65 years: <ul><li><strong>With kidney failure who require dialysis </strong>(or any other disease with a high chance of needing organ transplantation) at, or shortly after diagnosis.</li><li><strong>Who are about to undergo organ transplantation </strong>within a year before transplantation.</li><li><strong>Who are starting cytotoxic drugs for rheumatological disorders</strong> if the screening history is incomplete at the start of treatment.<ul><li>Any abnormality should be referred immediately to colposcopy.</li></ul></li><li><strong>Who are HIV positive</strong> at diagnosis and annually thereafter. Ideally, colposcopy should also be offered at diagnosis.</li></ul></li><li><strong>There is no indication for increased surveillance </strong>in women taking:<ul><li>Post-transplantation immunosuppressive drugs after the first year in women with no history of cervical intraepithelial neoplasia (CIN). However, a woman with an abnormal cervical cytology result should be referred promptly for colposcopy. </li><li>Cytotoxic chemotherapy for non-genital cancers.</li><li>Oestrogen antagonists (such as tamoxifen).</li><li>Cytotoxic drugs for rheumatological disorders or biologic agents for other disorders.</li><li>Alemtuzumab.</li></ul></li></ul><!-- end field e7601529-3bd6-4bed-8947-30d0a68f79cf --><!-- end item 01510e7b-2908-469c-bc20-817cfc98c089 -->","subChapters":[{"id":"69012cd5-81d5-5515-9d26-09d38ab3d77e","slug":"basis-for-recommendation-2f8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 19046ac3-f739-47ac-a3f4-b542d22a142b --><h4>Basis for recommendation</h4><!-- end field 19046ac3-f739-47ac-a3f4-b542d22a142b -->","summary":null,"htmlStringContent":"<!-- begin item 2f87b964-cdac-4ea4-bcc3-4c1e70041473 --><!-- begin field 62f42db9-9e87-4e92-a039-ee7b13325abd --><p>These recommendations are based on the Public Health England (PHE) guideline <em>NHS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016b</a>].</p><!-- end field 62f42db9-9e87-4e92-a039-ee7b13325abd --><!-- end item 2f87b964-cdac-4ea4-bcc3-4c1e70041473 -->","subChapters":[]}]},{"id":"bcf7e475-2f8b-57b2-ad60-4cce87393036","slug":"cervical-screening-post-cin-treatment","fullItemName":"Cervical screening post CIN treatment","depth":3,"htmlHeader":"<!-- begin field 2bbf7086-e173-45d7-9cb5-ef2765117520 --><h3>How often should women who have been treated for CIN be offered cervical screening?</h3><!-- end field 2bbf7086-e173-45d7-9cb5-ef2765117520 -->","summary":null,"htmlStringContent":"<!-- begin item 90ced90f-31df-4aaa-940e-8bb04d306314 --><!-- begin field a7fa1fe8-1769-4254-b6dc-f5f4f966fe94 --><ul><li><strong>It is important to encourage women to attend follow up, as women treated for cervical intraepithelial neoplasia (CIN) are at increased risk of developing cervical cancer.</strong></li><li>All women treated for CIN should be followed up for test of cure cervical cytology 6 months after treatment.<ul><li>If the sample is negative, borderline or low-grade, a reflex high-risk human papillomavirus (HR–HPV) test should be taken.<ul><li>Women who are HPV positive should be referred for colposcopy.</li><li>Women who are HPV negative should be recalled for repeated cytology in 3 years, irrespective of their age. </li></ul></li><li>If the sample is high-grade dyskaryosis or invasive squamous carcinoma, the woman should be referred for colposcopy. An HR-HPV test is unnecessary.</li></ul></li></ul><!-- end field a7fa1fe8-1769-4254-b6dc-f5f4f966fe94 --><!-- end item 90ced90f-31df-4aaa-940e-8bb04d306314 -->","subChapters":[{"id":"2325e54d-0e3f-58e0-9850-57461a2163c6","slug":"cervical-intraepithelial-neoplasia-cin","fullItemName":"Cervical intraepithelial neoplasia (CIN)","depth":4,"htmlHeader":"<!-- begin field 5e83527b-d72a-45bd-a449-192a4b7a13a6 --><h4>Cervical intraepithelial neoplasia (CIN)</h4><!-- end field 5e83527b-d72a-45bd-a449-192a4b7a13a6 -->","summary":null,"htmlStringContent":"<!-- begin item 20ac35f9-4b0b-4801-aa16-786be37c31b3 --><!-- begin field a9a42c5f-4325-4605-81c3-b25517c05153 --><ul><li><strong>Cervical intraepithelial neoplasia (CIN) is a premalignant lesion, detected by colposcopy. </strong></li><li><strong>It may exist at any one of three stages, and is </strong><strong>g</strong><strong>raded depending on how deep the cell changes go into the surface of the cervix:</strong><ul><li><strong>CIN1</strong> — one-third of the thickness of the surface layer of the cervix is affected.</li><li><strong>CIN2</strong> — two-thirds of the thickness of the surface layer of the cervix is affected.</li><li><strong>CIN3</strong> — sometimes called high-grade or severe dysplasia or stage 0 cervical carcinoma in situ. The full thickness of the surface layer is affected.</li></ul></li><li>Left untreated, CIN2 or CIN3 (collectively referred to as CIN2+) may progress to cervical cancer. </li><li>Usually (for all three grades) only a small part of the cervix has abnormal changes.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">Macmillan Cancer Support, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">WHO, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016a</a>]</p><!-- end field a9a42c5f-4325-4605-81c3-b25517c05153 --><!-- end item 20ac35f9-4b0b-4801-aa16-786be37c31b3 -->","subChapters":[]},{"id":"a029fdf9-32ed-5f78-a3ce-d143e5adea4d","slug":"basis-for-recommendation-e2e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f04e420f-bcaf-40ed-a758-9b0b090ba801 --><h4>Basis for recommendation</h4><!-- end field f04e420f-bcaf-40ed-a758-9b0b090ba801 -->","summary":null,"htmlStringContent":"<!-- begin item e2e7e3e4-c472-470d-8a68-23cfb202ae2f --><!-- begin field b7f8dbad-6349-4b8b-b734-b8cec3f37b99 --><p>These recommendations are based on the Public Health England (PHE) guideline <em>NHS cervical screening programme: colposcopy and programme management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016b</a>], and <em>NHS Cervical screening programme guidance for the training of cervical sample takers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016a</a>].</p><p><strong>Follow up of women treated for CIN </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-screening/references/\">PHE, 2016b</a>]</p><ul><li>Women who have been treated for CIN are 2–5 times more likely than the general population to develop cervical cancer, which may result from poor compliance with long term follow up. <ul><li>Several case series demonstrate that over 50% of cancers develop in women who are lost to follow up.</li></ul></li></ul><!-- end field b7f8dbad-6349-4b8b-b734-b8cec3f37b99 --><!-- end item e2e7e3e4-c472-470d-8a68-23cfb202ae2f -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}